Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index
December 16 2020 - 7:00AM
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical
company committed to developing medicines that transform the lives
of people with rare neurological diseases, today announced that it
has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI). The
addition will become effective prior to market open on Monday,
December 21, 2020.
The NASDAQ Biotechnology Index is designed to track the
performance of a set of securities listed on the NASDAQ Stock
Market® (NASDAQ®) that are classified as either biotechnology
or pharmaceutical according to the Industry Classification
Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked
annually and all securities in the index are listed on the NASDAQ
Global Market or the NASDAQ Global Select Market, and meet minimum
market value and share volume requirements among other criteria.
The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ
Biotechnology IndexSM Fund. In addition, options based on the
iShares NASDAQ Biotechnology Index Fund trade on various exchanges.
For more information about the NASDAQ Biotechnology Index visit
https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based
biopharmaceutical company using its BoldMedicine® approach to
develop medicines that transform the lives of patients with rare
neurological disorders. The Company is developing OV935
(soticlestat) in collaboration with Takeda Pharmaceutical Company
Limited, which is expected to initiate its pivotal clinical trials
in 2021 for the potential treatment of rare developmental and
epileptic encephalopathies (DEEs). OVID is evaluating the results
of the NEPTUNE trial of OV101 (gaboxadol) for the treatment of
Angelman syndrome and Fragile X syndrome. For more
information on Ovid, please visit www.ovidrx.com.
Contacts
Investors and Media:Ovid Therapeutics
Inc.Investor Relations & Public Relationsirpr@ovidrx.com
OR
Investors:Argot PartnersMaeve Conneighton/Dawn
Schottlandt212-600-1902ovid@argotpartners.com
Media:Dan Budwick1ABdan@1abmedia.com
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2023 to Apr 2024